IL-BAI
8.12.2022 19:43:43 CET | Business Wire | Press release
BAI, a nonprofit independent organization that delivers the most actionable insights in financial services, has named ten organizational winners and one honorable mention for the 2022 BAI Global Innovation Awards. Ten individuals were also named BAI Rising Stars. The awards are the industry’s leading program celebrating achievements in innovation, such as pursuing bold solutions for improving customer experience; implementing advanced technologies; and improving the lives of employees, customers, and communities.
Winners were selected by the BAI Innovation Circle, a panel of distinguished judges from around the world who are at the forefront of innovation in the financial services sector. Collectively, the winners represent outstanding contributions by teams and individuals and showcase inspiration from around the world. These global trailblazers have successfully designed and delivered innovations that positively improved customer relationships and served their communities in powerful ways.
“Innovation is a significant driver of the impact that successful financial services companies have on their customers and communities. The industry continues to bring powerful new approaches and solutions to better meet customer needs in new and different ways,” said Debbie Bianucci, president and CEO of BAI and Innovation Circle Judge. “The companies and individuals recognized this year were particularly creative and focused on addressing practical issues that made meaningful improvements for customers and employees.”
The 2022 BAI Global Innovation Award Winners and Honorable Mention are:
Banco Popular (Puerto Rico)
Innovation in Learning & Development
Innovation: Talent Lab & Skills Accelerator
Bank of America (USA)
Innovation in Digital Security
Innovation: Bank of America Security Center
Dreams Technology (United Kingdom)
Innovation in Digital Financial Planning
Innovation: Dreams ESG Innovation
Growsari (Philippines)
Innovation in Digital Commercial Financing
Innovation: GROWSARI.com, Powering the Digital Economy of the Philippines
Money Management International, Inc. (USA)
Innovation in Community Disaster Recovery
Innovation: Project Porchlight by MMI
MVB Bank (USA)
Innovation in Commercial Banking Onboarding Experience
Innovation: Onboarding Fintechs Better, Faster, Stronger…The Victor (ad)Vantage
Payten Teknoloji A.S.-Paratika (Turkey)
Innovation in Payments
Innovation: Paratika Crowdfunding e-Payment Project
Standard Bank (South Africa)
Innovation in Community Sustainability
Innovation: One Farm Share
TIAA (USA)
Innovation in Fraud Prevention
Innovation: TIAA Phone Authentication Risk Management (PARM)
Union Bank of India (India)
Innovation in HR Transformation
Innovation: Union Prerna
BMO (USA)
Innovation in Diversity, Equity & Inclusion (Honorable Mention)
Innovation: True Name
To further recognize innovation in financial services, a new award was established in 2022 to recognize individual leaders. The BAI Rising Star Award honors individuals who are up-and-coming leaders in financial services innovation. Leaders were nominated by their organizations and the recipients of the BAI Rising Star Award were selected based on their impact on and passion for innovation and their ability to drive positive change in their organizations.
The 2022 BAI Rising Star Award Winners are:
Sachin Chandna (United Arab Emirates), SVP, Head of Customer Intelligence & Engagement – Emirates NBD
Geoff Ellis (USA), Senior Director Application Development – Ally Financial
Ashley Fiore (USA), Chief Business Intelligence Officer – KlariVis
Snigdha Kumar (USA), Head of Product Operations – Digit
Larricia Lumpkins (USA), SVP, Senior Strategy Manager – Citizens Financial Group
Niki Neumann (South Africa), Executive, Lead Ecosystem Agriculture – Standard Bank Group
Dr. Chetna Pandey (India), Deputy General Manager – Union Bank of India
Stacy Regnier (USA), SVP, Retail Strategic Programs and Business Transformation – Commerce Bank
Bradwin Roper (South Africa), CEO – FNB Connect
Paul Whelpton (South Africa), Group Analytics Officer and Group Head of Trading – JUMO
For more information about the winners and their innovations, visit https://www.bai.org/globalinnovations/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom